CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-11-30): MRI-guided percutaneous cryotherapy effective for ablation of liver tumors

Clinical

MRI-guided percutaneous cryotherapy effective for ablation of liver tumors

Last Updated: 2004-11-30 14:45:03 -0400 (Reuters Health)

CHICAGO (Reuters Health) - Percutaneous cryotherapy under magnetic resonance imaging guidance achieved an overall 49% success rate in ablating liver tumors of 5 cm or less, according to research reported at the 90th scientific assembly and annual meeting of the Radiological Society of North America (RSNA).

Lead investigator Dr. Kemal Tuncali, an instructor in radiology at Brigham and Women's Hospital in Boston, said the success rate was 62% for smaller lesions (3.5 cm or less).

Dr. Tuncali said 34 patients with 47 liver tumors have been treated using MRI-guided cryotherapy, and he reported results from a series of 31 patients with 44 lesions. "Most of the lesions were metastases from aggressive cancers in the colon and other sites," he told Reuters Health. "Only two of the lesions were hepatocellular cancers."

Sixteen of the patients were women and the mean age was 62. The mean lesion size was 2.9 cm.

"We were able to treat 39 of 44 lesions and 17 of those required only one treatment," Dr. Tuncali said.

The procedure involves "initial rapid freezing, which takes about 15 minutes, a thawing for 10 minutes and then a second rapid freezing for 15 minutes. We know that cells die with rapid freezing, then additional death occurs with thawing, and finally the second freezing achieves additional cell death."

Among the complications associated with the treatment were "a transitory rise in bilirubin, a blood clot in the lung, liver bleeding, a clotting problem and a cancer nodule recurrence under the skin," Dr. Tuncali said. All complications responded to treatment and there were no fatalities associated with treatment.

He noted that recovery time "was quick and most patients were discharged after 24 hours."

The overall survival rate at 15 months is 77% in the current series.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.